The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early chemo-induced TME alterations as a predictor of response to PD-1 blockade in AVPC: Single-cell data from C3NIRA.
 
Anthos Christofides
No Relationships to Disclose
 
Sreyashi Basu
No Relationships to Disclose
 
Zhong He
No Relationships to Disclose
 
Rama Soundararajan
No Relationships to Disclose
 
Amado Zurita
No Relationships to Disclose
 
Bilal Siddiqui
Honoraria - Cancer Expert Now; Cardinal Health; Curio Science; DAVA Pharmaceuticals
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Johnson and Johnson; Merck; Pfizer; Survivornet
Research Funding - Amgen (Inst); Cancer Research Institute; Conquer Cancer, the ASCO Foundation; Johnson & Johnson/Janssen (Inst); Prostate Cancer Foundation; Regeneron (Inst)
Travel, Accommodations, Expenses - Cardinal Health; Curio Science; Merck
 
Sumit Subudhi
Stock and Other Ownership Interests - Apricity Health
Honoraria - Arcus Biosciences; Bristol Myers Squibb; Dendreon; Hervolution; Johnson & Johnson; Merck; Novartis
Consulting or Advisory Role - Pfizer
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Regeneron (Inst); Tarus Therapeutics (Inst)
 
Paul Corn
Research Funding - Janssen Oncology (Inst)
 
Craig Kovitz
Honoraria - Dendreon
Consulting or Advisory Role - Dendreon
 
Bagi Jana
Stock and Other Ownership Interests - Geron; Karyopharm Therapeutics
Consulting or Advisory Role - Cardinal Health; Novartis
Research Funding - Novartis (Inst)
 
Andrew Hahn
Honoraria - Binacea; Curio Science; Dava Oncology; IDEOlogy Health; Kaplan Partners in Knowledge; Mashup Media; Medscape; MJH Life Sciences
Consulting or Advisory Role - AVEO; Eisai; Exelixis; Intellisphere; Janssen Scientific Affairs; Pfizer; Tolmar
Research Funding - Bayer; Bristol Myers Squibb; Eisai (Inst); Halda Therapeutics
Travel, Accommodations, Expenses - Dava Oncology
 
Omar Alhalabi
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bicycle Therapeutics; Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst)
 
Jessica Deinert
Consulting or Advisory Role - Pfizer
 
Christopher Logothetis
No Relationships to Disclose
 
Timothy Thompson
Research Funding - Bayer
 
Rahul Sheth
No Relationships to Disclose
 
Patrick Pilié
Consulting or Advisory Role - Novartis; Pfizer
Patents, Royalties, Other Intellectual Property - Patent Pending- biomarker
 
Sangeeta Goswami
No Relationships to Disclose
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Akoya Biosciences; Akoya Biosciences (I); Apricity Health; Apricity Health (I); Bectas (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; InterVenn Biosciences (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Matrisome; Oncolytics; Osteologic; Osteologic Therpeutics (I); PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Affini-T Therapeutics; Apricity Health; Apricity Health (I); Asher Biotherapeutics; BioAtla; BioAtla (I); C-Reveal Therapeutics; Candel Therapeutics; Candel Therapeutics (I); Carisma Therapeutics; Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Henlius; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I); Xilis
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Ana Aparicio
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb Pharmaceuticals; Daiichi Sankyo; Genzyme; GlaxoSmithKline; Janssen; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; American Cancer Society; Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Daiichi Sankyo Inc.; Genzyme; GlaxoSmithKline; Janssen Research & Development; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Polaris (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; GlaxoSmithKline